Novel developments in the use of antimetabolites.

Novel developments in the use of antimetabolites.

Item
http://www.wikidata.org/entity/Q38221152
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesThe Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA.The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines.The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.Constitutive Expression of Inducible Cyclic Adenosine Monophosphate Early Repressor (ICER) in Cycling Quiescent Hematopoietic Cells: Implications for Aging Hematopoietic Stem Cells.The potential of multi-compound nanoparticles to bypass drug resistance in cancer.Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy
P2860

Novel developments in the use of antimetabolites.

Item
http://www.wikidata.org/entity/Q38221152
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Novel developments in the use of antimetabolites.
@en
type
label
Novel developments in the use of antimetabolites.
@en
prefLabel
Novel developments in the use of antimetabolites.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Novel developments in the use of antimetabolites.
@en
P2093
P2860
P304
P31
P356
10.1080/15257770.2014.894197
P433
P478
P577
P5875
P698